LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "bez235" as a keyword



The PI3K/mTOR dual inhibitor NVP‐BEZ235 stimulates mutant p53 degradation to exert anti‐tumor effects on triple‐negative breast cancer cells

Sign Up to like & get
recommendations! Published in 2020 at "FEBS Open Bio"

DOI: 10.1002/2211-5463.12806

Abstract: Nearly half of human cancers harbor p53 mutations, and mutant p53 (mutp53) promotes carcinogenesis, metastasis, tumor recurrence and chemoresistance. mutp53 is observed in 30% of breast carcinomas, including triple‐negative breast cancer (TNBC), and thus mutp53… read more here.

Keywords: degradation; bez235; tnbc; mutant p53 ... See more keywords

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Sign Up to like & get
recommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"

DOI: 10.1007/s00280-018-3610-z

Abstract: PurposeTo determine the maximum tolerated dose (MTD) of BEZ235, an oral inhibitor of class I PI3K and mTOR complexes 1 and 2.MethodsWe performed a phase I/Ib, multicenter, open-label study of oral BEZ235 administered in a… read more here.

Keywords: pi3k mtor; dose escalation; bez235; study ... See more keywords

A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors

Sign Up to like & get
recommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"

DOI: 10.1007/s00280-018-3725-2

Abstract: PurposeBEZ235 is a dual kinase inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin, which are key components of the PI3K pathway. This was an open-label, multicenter, dose-escalation, phase I study of single-agent BEZ235… read more here.

Keywords: solid tumors; advanced solid; bez235; study ... See more keywords

Anti-GPC3 Antibody-Conjugated BEZ235 Loaded Polymeric Nanoparticles (Ab-BEZ235-NP) Enhances Radiosensitivity in Hepatocellular Carcinoma Cells by Inhibition of DNA Double-Strand Break Repair.

Sign Up to like & get
recommendations! Published in 2020 at "Journal of biomedical nanotechnology"

DOI: 10.1166/jbn.2020.2834

Abstract: AIM To assess AB-BEZ235-NP potential as a radio-sensitizer in hepatocellular carcinoma models. METHOD By comparing hepatocellular carcinoma cell with simple radiation or combined AB-BEZ235-NP therapy, the HCC apoptosis and self-repair level have significant differences in… read more here.

Keywords: hepatocellular carcinoma; radiosensitivity; dna; bez235 ... See more keywords

NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma

Sign Up to like & get
recommendations! Published in 2018 at "Oncotarget"

DOI: 10.18632/oncotarget.23711

Abstract: Osteosarcoma(OS) remains a major health concern in childhood and adolescence, although cisplatin is one of the gold standard chemotherapeutic drugs in the treatment of OS, chemoresistant to cisplatin is common. Phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of… read more here.

Keywords: bez235; nvp bez235; osteosarcoma; cisplatin sensitivity ... See more keywords

Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer

Sign Up to like & get
recommendations! Published in 2019 at "Cancers"

DOI: 10.3390/cancers11081204

Abstract: Our previous study demonstrated that administration of NVP-BEZ235 (BEZ235), a dual PI3K/mTOR inhibitor, before radiotherapy (RT) enhanced the radiotherapeutic effect in colorectal cancer (CRC) cells both in vitro and in vivo. Here, we evaluated whether… read more here.

Keywords: treatment; bez235; maintenance bez235; bez235 mbez235 ... See more keywords

Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines

Sign Up to like & get
recommendations! Published in 2022 at "Cancers"

DOI: 10.3390/cancers14133160

Abstract: Simple Summary Head and neck cancers (HNSCCs), especially in the advanced stages, are predominantly treated by radiochemotherapy, including cisplatin. The cure rates are clearly higher for HPV-positive HNSCCs when compared to HPV-negative HNSCCs. For both… read more here.

Keywords: hpv negative; cisplatin radiation; bez235; hpv positive ... See more keywords